1. Home
  2. GIS vs ARGX Comparison

GIS vs ARGX Comparison

Compare GIS & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GIS
  • ARGX
  • Stock Information
  • Founded
  • GIS 1866
  • ARGX 2008
  • Country
  • GIS United States
  • ARGX Netherlands
  • Employees
  • GIS N/A
  • ARGX N/A
  • Industry
  • GIS Packaged Foods
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GIS Consumer Staples
  • ARGX Health Care
  • Exchange
  • GIS Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • GIS 31.9B
  • ARGX 35.3B
  • IPO Year
  • GIS N/A
  • ARGX 2017
  • Fundamental
  • Price
  • GIS $54.25
  • ARGX $573.26
  • Analyst Decision
  • GIS Hold
  • ARGX Strong Buy
  • Analyst Count
  • GIS 16
  • ARGX 20
  • Target Price
  • GIS $62.67
  • ARGX $698.22
  • AVG Volume (30 Days)
  • GIS 4.8M
  • ARGX 493.8K
  • Earning Date
  • GIS 06-25-2025
  • ARGX 05-08-2025
  • Dividend Yield
  • GIS 4.42%
  • ARGX N/A
  • EPS Growth
  • GIS 4.29
  • ARGX N/A
  • EPS
  • GIS 4.54
  • ARGX 15.94
  • Revenue
  • GIS $19,644,300,000.00
  • ARGX $2,643,062,000.00
  • Revenue This Year
  • GIS N/A
  • ARGX $61.64
  • Revenue Next Year
  • GIS N/A
  • ARGX $32.00
  • P/E Ratio
  • GIS $11.94
  • ARGX $32.97
  • Revenue Growth
  • GIS N/A
  • ARGX 82.13
  • 52 Week Low
  • GIS $52.39
  • ARGX $359.37
  • 52 Week High
  • GIS $75.90
  • ARGX $678.21
  • Technical
  • Relative Strength Index (RSI)
  • GIS 45.34
  • ARGX 45.96
  • Support Level
  • GIS $53.01
  • ARGX $570.00
  • Resistance Level
  • GIS $54.30
  • ARGX $584.90
  • Average True Range (ATR)
  • GIS 1.00
  • ARGX 14.55
  • MACD
  • GIS 0.13
  • ARGX 0.82
  • Stochastic Oscillator
  • GIS 62.84
  • ARGX 66.03

About GIS General Mills Inc.

General Mills is a global packaged food company that produces snacks, cereal, convenient meals, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Pillsbury, Betty Crocker, Blue Buffalo, and Haagen-Dazs. In fiscal 2024, 81% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. Although most of General Mills' products are sold through retail stores to consumers, the company also sells products to the foodservice channel and the commercial baking industry.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: